Bordeaux & Boston, 28 July, 2014 – IMPLANET (Paris:IMPL) (Euronext: IMPL, FR0010458729, PEA-PME eligible), a medical technology company specializing in vertebral and knee-surgery implants, today announced its revenue for the second quarter and first half of 2014.
Half-year 2014 sales of JAZZ exceed full year 2013 sales
In the first half of 2014, Implanet recorded revenue of EUR4,001 thousand (+21%), thanks to the buoyant sales dynamic of its Spine (JAZZ) and Knee ranges. Export revenue totaled EUR1,603 thousand over the first half and accounted for 40% of sales.
JAZZ is receiving a positive response in every region in which it is presented, resulting in 2.3x half-year revenue growth multiple, to EUR879 thousand. Over the first six months of the year alone, Implanet sold a total of 2,174 units (+127%), thus exceeding the total number of JAZZ implants sold in full year 2013 (1,953 units). During the first half, more than 300 surgeries were carried out using our JAZZ technology.
Solid first half performance for the Knee-surgery line
Revenue from the Group’s Knee activities recorded significant growth of +20%, totaling EUR2,357 thousand. This validates both the product development strategy and the distribution model changes adopted by management for this segment. In 2013, the Company altered the product mix, gradually withdrawing from Hip surgery and focusing on Knee surgery. The launch of a new ligament rebalancing system as well as the encouraging first developments of a revision implant system, will serve to strengthen the Company’s position in the Knee-surgery segment.
Continuation of the upsurge in JAZZ sales over the second quarter
Over the second quarter, the quarter in which Implanet typically records its lowest revenue, the Company reported revenue of EUR1,954 thousand (+40%), driven by the acceleration in JAZZ sales and by the solid performance in Knees. Export revenue totaled EUR798 thousand and accounted for 41% of total sales.
Over the quarter, revenue from the Company’s Spine activity (JAZZ) grew by a 3.2x multiple, totaling EUR455 thousand. The upsurge in JAZZ sales has been confirmed, with sequential growth of +7% over the first quarter of 2014. In the second quarter, Implanet sold a total of 1,102 units.
Revenue from Knees continued to grow, reaching EUR1,112 thousand (+33%), whilst the Company’s Hip activity saw sales decrease to EUR387 thousand (-9%), in accordance with its planned gradual withdrawal from this low value-added market.
Next financial press release: results for the third quarter of 2014, 15 September, 2014
About IMPLANET
Founded in 2007 and based near Bordeaux, IMPLANET is a medical technology company that manufactures high-quality implants for orthopedic surgery. Its flagship product, the JAZZ latest-generation implant, aims to improve the treatment of spinal pathologies requiring vertebral fusion surgery. Protected by four families of international patents, JAZZ has obtained 510(k) regulatory clearance from the Food and Drug Administration (FDA) in the United States and CE mark. IMPLANET employs 38 staff and recorded 2013 sales of EUR6.7 million.
For further information, please visit www.implanet.com